ALUNBRIG® (brigatinib) offers 1 tablet, once-daily dosing, or 365 pills per year4
up to 365 tablets / capsules a yeara
up to 730 tablets / capsules a yeara
up to 2,920 tablets / capsules a yeara
National Comprehensive Cancer Network® (NCCN®): recommends brigatinib as a Category 1, preferred first-line treatment option for ALK+ metastatic NSCLC5,b,c,d
Which of these other considerations is a top priority for you?
Connect with our team to learn more about how ALUNBRIG® (brigatinib) may be right for your patient
bWhen an ALK rearrangement is discovered prior to first-line systemic therapy.5
cThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques, but do not endorse any specific commercially available biomarker assays or commercial laboratories.
dSee the NCCN Guidelines® for detailed recommendations, including other preferred treatment options.
ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; mNSCLC, metastatic NSCLC; NSCLC, non-small cell lung cancer.